5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety

References

• Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014;43(2):476–93. doi:10.1093/ije/dyu034.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17:327–35.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. National survey on drug use and health: methodological summary and definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017 2016.
   Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62:593. doi:10.1001/archpsyc.62.6.593.
   PubMed Web of Science ®Google Scholar
• Harvard Medical School. National Comorbidity Survey (NCS) [Internet]. 2005 [cited 2017Aug21]. Available from: https://www.hcp.med.harvard.edu/ncs/index.php
   Google Scholar
• Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78–89. doi:10.1002/da.20580.
   PubMed Web of Science ®Google Scholar
• Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13(1):7–23.
   PubMedGoogle Scholar
• Niles AN, Dour HJ, Stanton AL, Roy-Byrne PP, Stein MB, Sullivan G, Sherbourne CD, Rose RD, Craske MG. Anxiety and depressive symptoms and medical illness among adults with anxiety disorders. J Psychosom Res. 2015;78(2):109–15. doi:10.1016/j.jpsychores.2014.11.018.
   PubMed Web of Science ®Google Scholar
• Cuijpers P, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis. World Psychiatry. 2014;13(1):56–67. doi:10.1002/wps.v13.1.
   PubMed Web of Science ®Google Scholar
• Otto MW, Hearon BA. Combination treatment for anxiety and mood disorders: benefits and issues for the combination of cognitive-behavioral therapy and pharmacotherapy. In: Nezu CM, Nezu, AM, editors. The Oxford handbook of cognitive and behavioral therapies.New York, NY: Oxford University Press; 2016. p. 482–93.
   Google Scholar
• Collins KA, Westra HA, Dozois DJ, Burns DD. Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clin Psychol Rev. 2004;24(5):583–616. doi:10.1016/j.cpr.2004.06.001.
   PubMed Web of Science ®Google Scholar
• Collimore KC, Rector NA. Treatment of anxiety disorders with comorbid depression: a survey of expert CBT clinicians. Cogn Behave Pract. 2014;21(4):485–93. doi:10.1016/j.cbpra.2014.01.007.
   Web of Science ®Google Scholar
• Coull G, Morris PG. The clinical effectiveness of CBT-based guided self-help interventions for anxiety and depressive disorders: a systematic review. Psychol Med. 2011;41(11):2239–52. doi:10.1017/S0033291711000900.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cognit Ther Res. 2012;36(5):427–40. doi:10.1007/s10608-012-9476-1.
   PubMed Web of Science ®Google Scholar
• Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychaitry. 2010;55(3):126–35. doi:10.1177/070674371005500303.
   PubMed Web of Science ®Google Scholar
• Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci. 2011;13(4):423–37.
   PubMedGoogle Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard J, Forbes B, Feilding A, et al. Psilocybin with psychological support for treatment-resistant depression: an open label feasibility study. The Lancet Psychiatry. 2016; 3(7):619–27. doi:10.1016/S2215-0366(16)30065-7.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Griffiths RR. Potential therapeutic effects of psilocybin. Neurotherapeutics. 2017;14(3):734–40. doi:10.1007/s13311-017-0542-y.
   PubMed Web of Science ®Google Scholar
• Araújo AM, Carvalho F, Bastos MD, Pinho PG, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol. 2015;89(8):1151–73. doi:10.1007/s00204-015-1513-x.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol. 2011 Nov; 25(11): 1562–67. doi:10.1177/0269881110367445.
   PubMed Web of Science ®Google Scholar
• Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology (Berl). 2017;235(2):459–66. doi:10.1007/s00213-017-4754-y.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, Mcgonigle J, Nutt DJ. Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci Rep. 2017;7:1. doi:10.1038/s41598-017-13282-7.
   PubMed Web of Science ®Google Scholar
• Ross S, Bossis T, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga S, Belser A, Kalliontzi K, Babb J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–80. doi:10.1177/0269881115622590.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–97. doi:10.1177/0269881115622590.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621–32. doi:10.1177/0269881108091069.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose related effects. Psychopharmacology (Berl). 2011;218(4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974. doi:10.3389/fphar.2017.00974.
   PubMed Web of Science ®Google Scholar
• Pharmepéna-Psychonautics: OJ, Intranasal H. Sublingual and Oral Pharmacology of 5-Methoxy-N, N-Dimethyl-Tryptamine. J Psychoactive Drugs. 2001;33(4):403–07. doi:10.1080/02791072.2001.10399925.
   PubMed Web of Science ®Google Scholar
• Shulgin AT, Shulgin A. Tihkal: the continuation. Berkeley, CA: Transform Press; 1997.
   Google Scholar
• Davis AK, Barsuglia JP, Lancelotta R. Grant R and Renn E. The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol. 2018;32(7):779–92. doi:10.1177/0269881118769063.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268–83. discussion 284–92 doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Drug Enforcement Administration (DEA). Department of Justice. Schedules of Controlled Substances: Placement of 5-Methoxy-N,N-Dimethyltryptamine into Schedule I of the Controlled Substances Act. Final Rule. Fed Regist., 2010;75(243):79296–300.
   Google Scholar
• Maclean KA, Leoutsakos J-MS, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig. 2012;51(4):721–37. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Johnson MW, Griffiths RR. Validation of the revised mystical experiences questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29(11):1182–90. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Bradstreet MP, Leoutsakos J-MS, Johnson MW, Griffiths RR. The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol. 2016;30(12):1279–95. doi:10.1177/0269881115622590.
   PubMed Web of Science ®Google Scholar
• Amrhein V, Korner-Nievergelt F, Roth T. The earth is flat (p > 0.05): significance thresholds and the crisis of unreplicable research. PeerJ. 2017;5:e3544. doi:10.7717/peerj.3544.
   PubMed Web of Science ®Google Scholar
• Perneger TV. What’s wrong with Bonferroni adjustments. Bmj. 1998; 316(7139):1236–38. doi:10.1136/bmj.316.7139.1236.
   PubMed Web of Science ®Google Scholar
• Rubin M. Do p values lose their meaning in exploratory analyses? It depends how you define the familywise error rate. Rev Gen Psychol. 2017; 21(3):269–75. doi:10.1037/gpr0000123.
   Web of Science ®Google Scholar
• IBM Corp. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.; 2016.
   Google Scholar
• Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157–64. doi:10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–78. doi:10.1177/0269881115622590.
   PubMed Web of Science ®Google Scholar
• Newby JM, Mckinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. Clin Psychol Rev. 2015;40:91–110. doi:10.1016/j.cpr.2015.06.002.
   PubMed Web of Science ®Google Scholar